Mizuho Issues Pessimistic Forecast for Boston Scientific (NYSE:BSX) Stock Price

Boston Scientific (NYSE:BSX) had its price objective cut by analysts at Mizuho from $140.00 to $115.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage presently has an “outperform” rating on the medical equipment provider’s stock. Mizuho’s price objective would indicate a potential upside of 52.32% from the company’s current price.

Several other brokerages have also recently issued reports on BSX. Wells Fargo & Company raised their target price on shares of Boston Scientific from $124.00 to $125.00 and gave the stock an “overweight” rating in a report on Thursday, October 23rd. Royal Bank Of Canada increased their price target on shares of Boston Scientific from $125.00 to $130.00 and gave the company an “outperform” rating in a research report on Wednesday, December 17th. BTIG Research restated a “buy” rating on shares of Boston Scientific in a research report on Wednesday. Wall Street Zen raised shares of Boston Scientific from a “hold” rating to a “buy” rating in a research note on Saturday, January 17th. Finally, The Goldman Sachs Group reissued a “buy” rating and issued a $112.00 target price on shares of Boston Scientific in a research note on Friday, January 9th. One research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, Boston Scientific presently has an average rating of “Moderate Buy” and an average target price of $115.75.

Boston Scientific Stock Down 17.6%

Shares of NYSE:BSX opened at $75.50 on Thursday. The stock has a market capitalization of $111.92 billion, a P/E ratio of 40.37, a price-to-earnings-growth ratio of 1.63 and a beta of 0.67. The stock’s 50-day moving average price is $94.37 and its 200-day moving average price is $99.13. The company has a current ratio of 1.51, a quick ratio of 0.96 and a debt-to-equity ratio of 0.47. Boston Scientific has a 12-month low of $75.00 and a 12-month high of $109.50.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, beating analysts’ consensus estimates of $0.78 by $0.02. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.The company had revenue of $5.29 billion during the quarter, compared to analyst estimates of $5.29 billion. During the same quarter in the previous year, the company posted $0.70 EPS. Boston Scientific’s revenue for the quarter was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, equities analysts anticipate that Boston Scientific will post 2.85 earnings per share for the current year.

Insider Activity at Boston Scientific

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the sale, the executive vice president directly owned 23,600 shares of the company’s stock, valued at approximately $2,396,580. The trade was a 42.32% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Michael F. Mahoney sold 160,901 shares of the stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the transaction, the chief executive officer directly owned 1,411,735 shares of the company’s stock, valued at $131,983,105.15. This represents a 10.23% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 0.50% of the company’s stock.

Institutional Trading of Boston Scientific

A number of hedge funds have recently modified their holdings of the business. Norges Bank bought a new position in shares of Boston Scientific in the 2nd quarter worth about $2,089,937,000. Edgewood Management LLC purchased a new stake in Boston Scientific in the second quarter worth about $746,655,000. Parnassus Investments LLC increased its stake in shares of Boston Scientific by 42,978.9% during the third quarter. Parnassus Investments LLC now owns 6,884,440 shares of the medical equipment provider’s stock valued at $672,128,000 after purchasing an additional 6,868,459 shares in the last quarter. Egerton Capital UK LLP lifted its holdings in shares of Boston Scientific by 223.7% during the third quarter. Egerton Capital UK LLP now owns 5,312,504 shares of the medical equipment provider’s stock valued at $518,660,000 after purchasing an additional 3,671,548 shares during the last quarter. Finally, Bessemer Group Inc. boosted its position in shares of Boston Scientific by 14,391.8% in the 2nd quarter. Bessemer Group Inc. now owns 2,919,801 shares of the medical equipment provider’s stock worth $313,618,000 after purchasing an additional 2,899,653 shares in the last quarter. Institutional investors own 89.07% of the company’s stock.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Q4 results beat expectations — adjusted EPS of $0.80 and $5.29B in revenue with ~16% reported sales growth and margin improvement, confirming underlying top‑line momentum. Boston Scientific announces results for fourth quarter and full year 2025
• Positive Sentiment: Operational growth and beat on consensus EPS give the company credibility that core businesses are expanding, supporting longer‑term revenue prospects. Boston Scientific (BSX) Beats Q4 Earnings and Revenue Estimates
• Neutral Sentiment: Wall Street still has a majority of buy ratings and an above‑current consensus price target, suggesting analysts may be cautious but not uniform in selling. MarketBeat BSX profile
• Negative Sentiment: Guidance disappointed: FY‑2026 EPS and revenue ranges came in modest and slightly below consensus in places, and Q1 guidance was cautious — this trimmed near‑term growth expectations and triggered the selloff. Boston Scientific shares slide on cautious 2026 revenue forecast
• Negative Sentiment: Electrophysiology and a key hyped device underperformed expectations, prompting concern that some growth drivers will be weaker than modeled. Boston Scientific hits an 18-month low on a ‘sore spot’ for its most hyped device
• Negative Sentiment: Market reaction amplified by heavy bearish activity and a sharp intraday drop (including a 52‑week/18‑month low); options flow showed a surge in put buying, signaling short‑term bearish positioning. BSX Earnings: Boston Scientific Stock (BSX) Plunges 17% on Weak Guidance
• Negative Sentiment: Large insider sale disclosed (CEO sold ~160,901 shares), which may add to investor nervousness despite the company’s fundamentals. SEC filing: Insider sale by Michael Mahoney

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.